

Partnering Opportunities

TNFR2 Agonist Antibody Program (MM-401)

- Exciting Immuno-oncology Drug Candidate Against Novel Immunotherapy Target with Opportunity to be First in Class
- Preclinical program with extensive best in class mechanism and preclinical data:
 - Agonistic mechanism of action provides unique efficacy & safety
 - Co-stimulatory activity via TNFR2 signaling induces proliferation and activation T cells *in vitro* and *in vivo*
 - Fcγ receptor binding essential for activity, but does not lead to significant depletion of cells (e.g. Tregs)
 - Robust anti-tumor activity in preclinical models
 - Complete or significant responses in multiple mouse syngeneic and human PBMC and PDX tumor models as a monotherapy
 - Superior survival across multiple syngeneic models when combined with PD-1/PD-L1
 - Induction of long-term anti-tumor memory in mice, no tumor growth in re-challenge studies
- Development status:
 - Two lead agonist antibodies selected and ready for cell line development
 - Favorably toxicity profile compared to antibodies targeting other T cell receptors
 - Clinical opportunities as monotherapy and I/O combination therapy
 - Initial PD strategy developed for patient selection
 - Patent applications pending
- Tam *et al.*, *Sci Transl. Med.* 11, eaax0720 (2019)

TRAIL DR4/DR5 Agonist Program (MM-201)

- Preclinical program superior to first generation agonists with robust preclinical package
 - Stable protein molecule with long half life
 - Superior safety and efficacy and safety shown compared to other TRAIL molecules
 - Anti-tumor activity demonstrated in multiple CRC-PDX models, as a monotherapy and in synergistic combination with SoC drugs
- Development status:
 - Lead candidates with CMC characteristics
 - CRC and Sarcoma identified as initial indications from multiple preclinical studies, with prostate cancer and multiple myeloma data as well
 - Biomarker strategy investigated
 - Patent applications pending

For more info, please email: BusDev@merrimack.com